Why Did Penumbra Stock Soar 14.46%?

On July 30, 2025, Penumbra's stock surged by 14.46% in pre-market trading, reflecting a strong market response to the company's recent financial performance and strategic developments.

Penumbra reported impressive second-quarter results for 2025, with revenue reaching $339.5 million, marking a 13.4% year-over-year increase. This growth was driven by strong sales across its product portfolio, particularly in the embolization segment. The company's earnings per share also exceeded expectations, coming in at $0.86 per share, surpassing the consensus estimate of $0.81 per share.

Analysts have maintained a bullish outlook on Penumbra, with William Blair's Brandon Vazquez reiterating a Buy rating on July 23. Vazquez highlighted the company's strong performance in overseas embolization and the introduction of new products and markets, which are expected to support continued growth. The upcoming results from the STORM-PE study and the anticipated approval of Thunderbolt for stroke treatment are also seen as potential growth drivers for 2026.

Despite concerns about a potential slowdown in the second half of the year, Vazquez believes that Penumbra's strategic initiatives, such as the establishment of new sales teams for embolization and vascular products, will enhance market penetration and present compelling opportunities for investors.